Study Explores Prostate Cancer Among Men with Low PSA Levels (7/30/2010)
In a large U.S. cancer database, 14% of prostate cancer diagnoses occurred among men with a prostate-specific antigen (PSA) level of 4.0 ng/mL or lower. More than half of these men had cancer that was considered “low-risk,” but roughly three-quarters were treated aggressively with radical prostatectomy or radiation therapy. These results were published in the Archives of Internal Medicine.

Statins May Reduce Risk of Prostate Cancer Recurrence (7/2/2010)
Statin use may reduce the risk of prostate cancer recurrence among men who have undergone a radical prostatectomy. These findings were recently published in the journal Cancer.

Watchful Waiting May Be Sufficient in Low-risk Prostate Cancer (6/30/2010)
Active surveillance—sometimes referred to as “watchful waiting”—may be acceptable treatment for low-risk prostate cancer, according to the results of a study published early online in the Journal of the National Cancer Institute.

Jevtana Approved for Hormone-refractory Prostate Cancer (6/21/2010)
Jevtana® (cabazitaxel), a new chemotherapy drug, was approved for use in combination with prednisone for the treatment of patients with metastatic hormone-refractory prostate cancer previously treated with a Taxotere® (docetaxel)-containing regimen.

Addition of Radiation to Hormone Therapy Improves Survival in Locally Advanced Prostate Cancer (6/8/2010)
The addition of radiation therapy to hormone therapy reduces the risk of prostate cancer death by 43% among men with locally advanced or high-risk prostate cancer compared with hormone therapy alone, according to the results of a phase III study presented at the 2010 annual meeting of the American Society of Clinical Oncology.